Transformative secures £1.7m seed funding led by Tera Ventures to advance predictive cardiac software.
Tera Ventures led the seed financing round for the medical software startup, with participation from the Wellcome Trust and InHealth Ventures.
Transformative is a medical software company that develops predictive patient monitoring tools to identify imminent life-threatening medical events. Its patented technology focuses on forecasting in-hospital sudden cardiac arrest.
Transformative has secured a £1.7m seed round led by Tera Ventures, with additional backing from the Wellcome Trust and InHealth Ventures. The fresh capital will be directed towards obtaining FDA clearance for the company's inaugural product and expanding its predictive healthcare technology offerings. The round also sees the addition of new board members from Tera Ventures and AI Seed.
The startup's core software uses hospital monitoring data to predict sudden cardiac arrest hours in advance, addressing a critical clinical need for early intervention. This development arrives as health authorities continue to emphasise preventive care to improve survival rates from cardiac events globally.
From the founder
"On each shift, I experience the tragedy of delayed care and the marvel of early, preventive interventions,"
Josh Oppenheimer
Co-founder and CEO at Transformative
Investor perspective
"investing in future technologies is essential so that the younger generation of researchers and innovators can develop solutions that will affect the future of all humankind."
Andrus Oks
Tera Ventures
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Categories
About the company
Transformative
Transformative builds software that predicts sudden cardiac arrest using hospital patient monitoring data.